Recent progress of clinical trials in urologic oncology

Shiro Hinotsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In Japan, after New Good Clinical Practice put into operation, it has became improved the environment of conducting clinical trials for new drug approval. Clinical trial supporting system, such as data management system, have been developing. It is important to introduce the know-how into clinical trials that is not for new drug approval. Randomized controlled clinical trials are considered to be high evidence level study design. In some fields, it is very difficult and is not appropriate to conduct randomized controlled trials. In such fields, it is appropriate for well designed descriptive studies. And it should be accepted as high evidence level study for well designed descriptive studies. For cytostatic antineoplastic agents, it should be introduced new evaluation method such as randomized discontinuation design.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume33
Issue number2
Publication statusPublished - Feb 2006
Externally publishedYes

Fingerprint

Drug Approval
Clinical Trials
Randomized Controlled Trials
Cytostatic Agents
Information Systems
Antineoplastic Agents
Japan

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

Recent progress of clinical trials in urologic oncology. / Hinotsu, Shiro.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 33, No. 2, 02.2006, p. 188-192.

Research output: Contribution to journalArticle

@article{2e4286c9b18843a6aebc3e033d0e7de2,
title = "Recent progress of clinical trials in urologic oncology",
abstract = "In Japan, after New Good Clinical Practice put into operation, it has became improved the environment of conducting clinical trials for new drug approval. Clinical trial supporting system, such as data management system, have been developing. It is important to introduce the know-how into clinical trials that is not for new drug approval. Randomized controlled clinical trials are considered to be high evidence level study design. In some fields, it is very difficult and is not appropriate to conduct randomized controlled trials. In such fields, it is appropriate for well designed descriptive studies. And it should be accepted as high evidence level study for well designed descriptive studies. For cytostatic antineoplastic agents, it should be introduced new evaluation method such as randomized discontinuation design.",
author = "Shiro Hinotsu",
year = "2006",
month = "2",
language = "English",
volume = "33",
pages = "188--192",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Recent progress of clinical trials in urologic oncology

AU - Hinotsu, Shiro

PY - 2006/2

Y1 - 2006/2

N2 - In Japan, after New Good Clinical Practice put into operation, it has became improved the environment of conducting clinical trials for new drug approval. Clinical trial supporting system, such as data management system, have been developing. It is important to introduce the know-how into clinical trials that is not for new drug approval. Randomized controlled clinical trials are considered to be high evidence level study design. In some fields, it is very difficult and is not appropriate to conduct randomized controlled trials. In such fields, it is appropriate for well designed descriptive studies. And it should be accepted as high evidence level study for well designed descriptive studies. For cytostatic antineoplastic agents, it should be introduced new evaluation method such as randomized discontinuation design.

AB - In Japan, after New Good Clinical Practice put into operation, it has became improved the environment of conducting clinical trials for new drug approval. Clinical trial supporting system, such as data management system, have been developing. It is important to introduce the know-how into clinical trials that is not for new drug approval. Randomized controlled clinical trials are considered to be high evidence level study design. In some fields, it is very difficult and is not appropriate to conduct randomized controlled trials. In such fields, it is appropriate for well designed descriptive studies. And it should be accepted as high evidence level study for well designed descriptive studies. For cytostatic antineoplastic agents, it should be introduced new evaluation method such as randomized discontinuation design.

UR - http://www.scopus.com/inward/record.url?scp=33644861068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644861068&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 188

EP - 192

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -